Literature DB >> 15176680

Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD.

D Banerjee1, O A Khair, D Honeybourne.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by sputum production, bacterial colonisation, neutrophilic bronchial airway inflammation and poor health status. The aim of this study was to determine the impact of sputum potentially pathogenic microorganisms (PPMs) on bronchial airway inflammation, health status and plasma fibrinogen levels in subjects with moderate-to-severe COPD during the clinical stable state. Sputum total cell and neutrophil counts, supernatant interleukin-8, leukotriene B4, tumour necrosis factor-alpha and neutrophil elastase levels, neutrophil chemotaxis and plasma fibrinogen levels were estimated. Health status was determined using the St George's Respiratory Questionnaire and the 36-item Short-Form Health Survey questionnaire. Twenty-seven (40%) subjects had PPMs and 40 (60%) non-PPMs in their sputum. Both groups were of similar age, body mass index, smoking history and lung function. The PPMs group showed significantly higher levels of interleukin-8, leukotriene B4, tumour necrosis factor-a, neutrophil elastase and increased neutrophil chemotaxis. They also exhibited worse health status and raised plasma fibrinogen levels compared to the non-PPMs group. In conclusion, subjects with clinically stable moderate-to-severe chronic obstructive pulmonary disease who had potentially pathogenic microorganisms in their sputum demonstrated an exaggerated airway inflammatory response, poorer health status and increased plasma fibrinogen levels than those who had nonpotentially pathogenic microorganisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176680     DOI: 10.1183/09031936.04.00056804

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  59 in total

1.  Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease.

Authors:  M Zhang; Q Li; X-Y Zhang; X Ding; D Zhu; X Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-20       Impact factor: 3.267

2.  Repeated Exposure to Streptococcus pneumoniae Exacerbates Chronic Obstructive Pulmonary Disease.

Authors:  Xuxu Gou; Qiao Zhang; Sunil More; Gayan Bamunuarachchi; Yurong Liang; Faizan Haider Khan; Rachel Maranville; Emily Zuniga; Changzheng Wang; Lin Liu
Journal:  Am J Pathol       Date:  2019-06-18       Impact factor: 4.307

3.  Multivariate analysis of the risk for pulmonary complication after gastrointestinal surgery.

Authors:  Shan-Ping Jiang; Zhi-Ying Li; Li-Wen Huang; Wei Zhang; Zhi-Qiang Lu; Zhi-Yong Zheng
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Jane Maloney; Lori Grove; Catherine Wrona; Charles S Berenson
Journal:  Am J Respir Crit Care Med       Date:  2006-02-10       Impact factor: 21.405

5.  The lung tissue microbiome in chronic obstructive pulmonary disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Shizu Hayashi; W Mark Elliott; John E McDonough; John V Gosselink; Joel Cooper; Don D Sin; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

Review 6.  Inflammatory cells in the airways in COPD.

Authors:  R O'Donnell; D Breen; S Wilson; R Djukanovic
Journal:  Thorax       Date:  2006-05       Impact factor: 9.139

Review 7.  Chronic obstructive pulmonary disease: role of bacteria and updated guide to antibacterial selection in the older patient.

Authors:  G Iyer Parameswaran; Timothy F Murphy
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Newer fluoroquinolones in the treatment of acute exacerbations of COPD.

Authors:  Amit Patel; Robert Wilson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.